US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

12.08

+0.84007.47%

Pre-market: 11.71-0.3700-3.06%04:06 EDT

Volume:2.52M

Turnover:30.30M

Market Cap:1.66B

PE:-2.34

High:12.50

Open:11.04

Low:10.95

Close:11.24

Loading ...

Overview Company News Filings

Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer

MT Newswires Live

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

THOMSON REUTERS

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

BRIEF-Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO

Arrowhead Pharmaceuticals Inc - Ken Myszkowski to Retire as CFO of Arrowhead Pharmaceuticals - SEC Filing

THOMSON REUTERS

Arrowhead Pharmaceuticals CEO Makes a Major Stock Sale!

This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. -- Barrons.com

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses

Simply Wall St.

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Arrowhead data supports blockbuster potential of ARO-C3, says H.C. Wainwright

Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements

Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients

MT Newswires Live

BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy

Arrowhead announces topline results from ARO-C3 trial

Arrowhead Pharmaceuticals Inc - Aro-C3 Generally Well-Tolerated in Patients With Igan

THOMSON REUTERS

Arrowhead Pharmaceuticals Announces Topline Results From Part 2 of Phase 1/2 Study of Aro-C3 in Patients With Iga Nephropathy

THOMSON REUTERS

Arrowhead Pharmaceuticals Inc - No Serious or Severe Treatment Emergent Adverse Events Reported

THOMSON REUTERS

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ARWR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARWR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARWR\",,,,,undefined,":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Pharmaceuticals","latestPrice":12.08,"timestamp":1745265600000,"preClose":11.24,"halted":0,"volume":2521336,"hourTrading":{"tag":"盘前","latestPrice":11.71,"preClose":12.08,"latestTime":"04:06 EDT","volume":2,"amount":23.529998,"timestamp":1745309196966},"delay":0,"floatShares":119000000,"shares":137317373,"eps":-5.153072,"marketStatus":"Pre-Mkt","change":0.84,"latestTime":"04-22 07:27:16 EDT","open":11.04,"high":12.5,"low":10.95,"amount":30295914.492847998,"amplitude":0.1379,"askPrice":12.2,"askSize":1,"bidPrice":12.11,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-5.153072,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":12.08,"preHourTrading":{"tag":"盘前","latestPrice":11.71,"preClose":12.08,"latestTime":"04:06 EDT","volume":2,"amount":23.529998,"timestamp":1745309196966},"postHourTrading":{"tag":"盘后","latestPrice":12.08,"preClose":12.08,"latestTime":"18:20 EDT","volume":47972,"amount":579499.82,"timestamp":1745274021110},"volumeRatio":1.1280667941050893,"optionData":{"bulkOrders":[{"symbol":"ARWR","call":false,"expireDate":1750392000000,"strike":"10.0","timestamp":1745245525239,"price":0.55,"volume":7500,"amount":412500,"type":"-"}]},"impliedVol":0.9038,"impliedVolPercentile":0.9598},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARWR\",,,,,undefined,":{"symbol":"ARWR","floatShares":119000000,"roa":"-47.71%","roe":"-565.33%","lyrEps":-5.004783,"volumeRatio":1.1280667941050893,"shares":137317373,"dividePrice":0,"high":12.5,"amplitude":0.1379,"preClose":11.24,"low":10.95,"week52Low":9.57,"pbRate":"31.54","psRate":"663.52","week52High":30.41,"institutionHeld":0.9542,"latestPrice":12.08,"eps":-5.153072,"divideRate":0,"volume":2521336,"delay":0,"ttmEps":-5.153072,"open":11.04,"prevYearClose":18.8,"prevWeekClose":11.24,"prevMonthClose":12.74,"prevQuarterClose":12.74,"fiveDayClose":11.79,"twentyDayClose":14.8,"sixtyDayClose":21.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARWR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527420616","title":"Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527420616","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527420616?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:28","pubTimestamp":1744748901,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said late Tuesday it has appointed Daniel Apel as its chief financial officer, effective May 13, succeeding Ken Myszkowski, who will retire.Myszkowski will continue to offer his services as an employee adviser to ensure a smooth transition, the company said.Apel previously worked as global head of financial planning and analysis at Walgreens Boots Alliance , Arrowhead said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0321505439.SGD","BK4128","BK4139","WBA.AU","ARWR","LU0321505868.SGD","WBA","BK4588"],"gpt_icon":0},{"id":"2527197422","title":"Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527197422","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527197422?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:00","pubTimestamp":1744747200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA2BGD6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARWR","BK4585","BK4588"],"gpt_icon":0},{"id":"2527224724","title":"Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527224724","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527224724?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:00","pubTimestamp":1744747200,"startTime":"0","endTime":"0","summary":"PASADENA, Calif., April 15, 2025----Arrowhead Pharmaceuticals, Inc.  today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company’s new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition.\"Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans. I want to thank him for all his important contributions to Arrowhead,\" said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. \"I am also excited for Dan Apel to join Arrowhead as we make the transition from development stage to commercial stage, with the planned launch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-appoints-daniel-apel-200000334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","LU1169590202.USD","ARWR","LU1169589451.USD","BK4139","BIO","BK4121"],"gpt_icon":0},{"id":"2527042268","title":"BRIEF-Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2527042268","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527042268?lang=en_us&edition=fundamental","pubTime":"2025-04-16 03:51","pubTimestamp":1744746707,"startTime":"0","endTime":"0","summary":"BRIEF-Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFOApril 15  - Arrowhead Pharmaceuticals Inc ARWR.O:ARROWHEAD PHARMACEUTICALS INC - KEN MYSZKOWSKI TO RETIRE AS CFO OF ARROWHEAD PHARMACEUTICALS - SEC FILINGARROWHEAD PHARMACEUTICALS INC - DANIEL APEL APPOINTED AS CFO OF ARROWHEAD PHARMACEUTICALS - SEC FILINGSource text: [ID:n0001628280-25-017844]Further company coverage: ARWR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARWR","BK4139","BK4588"],"gpt_icon":0},{"id":"2527742257","title":"Arrowhead Pharmaceuticals Inc - Ken Myszkowski to Retire as CFO of Arrowhead Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527742257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527742257?lang=en_us&edition=fundamental","pubTime":"2025-04-16 03:50","pubTimestamp":1744746651,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARWR","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2526620022","title":"Arrowhead Pharmaceuticals CEO Makes a Major Stock Sale!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526620022","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526620022?lang=en_us&edition=fundamental","pubTime":"2025-04-12 10:01","pubTimestamp":1744423272,"startTime":"0","endTime":"0","summary":"New insider activity at Arrowhead Pharmaceuticals ( ($ARWR) ) has taken place on April 12, 2025. CEO Christopher Richard Anzalone has recently sold...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/arrowhead-pharmaceuticals-ceo-makes-a-major-stock-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/arrowhead-pharmaceuticals-ceo-makes-a-major-stock-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ARWR","BK4139","BK4588"],"gpt_icon":0},{"id":"2525057546","title":"This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2525057546","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525057546?lang=en_us&edition=fundamental","pubTime":"2025-04-07 13:00","pubTimestamp":1744002000,"startTime":"0","endTime":"0","summary":"About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can't treat.However, Eli Lilly reported late last month that just one shot of an experimental drug eliminated most of this type of bad cholesterol, known as lipoprotein, for six months.Lilly is now enrolling patients for a Phase 3 trial of its drug, lepodisiran. Amgen has already recruited its Phase 3 study of olpasiran, a rival treatment for lipoprotein that is as powerful, if not quite as long-acting. Ahead of both is Novartis, whose Phase 3 trial of a monthly injection called pelacarsen could report results this year.These drugmakers are targeting a troublesome cholesterol variant that is a risk factor for cardiovascular disease distinct from the kind of cholesterol that is treated with statins. Since one to two billion people worldwide are born with high levels of lipoprotein, successful drugs should have a big market.Now, the companies have to show that lowering ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203201768.USD","LU0203202063.USD","LU1061106388.HKD","LU0385154629.USD","BK4007","LU0672654240.SGD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU2237443622.USD","LU0109391861.USD","LU1868836914.USD","LU2265009873.SGD","AMGN","IE00BK4W5M84.HKD","LU0106261372.USD","LU1093756168.USD","IE0002141913.USD","LU0471298694.HKD","LU1988902786.USD","LU2242652126.USD","IE00B2B36J28.USD","LU1868837300.USD","IE00B1BXHZ80.USD","BK4534","SGXZ99366536.SGD","LU1814569148.SGD","LU2237443549.SGD","LLY","LU0320765059.SGD","SG9999015978.USD","LU2491050071.SGD","LU1868836591.USD","LU2461242641.AUD","SG9999015952.SGD","LU0417517546.SGD","BK4581","SG9999018865.SGD","LU2361044865.SGD","LU2237443978.SGD","SG9999014906.USD","LU2468319806.SGD","SLN","IE00BJLML261.HKD","LU0471298777.SGD","LU0354030511.USD","ARWR","LU0882574139.USD","LU1280957306.USD","LU2491049909.HKD"],"gpt_icon":1},{"id":"2525307197","title":"Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525307197","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525307197?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:30","pubTimestamp":1743798600,"startTime":"0","endTime":"0","summary":"PASADENA, Calif., April 04, 2025----Arrowhead Pharmaceuticals, Inc.  today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company’s Board of Directors approved \"inducement\" grants to 21 new employees under Rule 5635 of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-reports-inducement-grants-203000518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ARWR","NDAQ","IE00B64PRP62.GBP","BK4588",".IXIC","LU2095319765.USD","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2518278188","title":"Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278188","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518278188?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:04","pubTimestamp":1741629841,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/institutional-investors-may-adopt-severe-steps-after-arrowhe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","NDAQ","ARWR"],"gpt_icon":0},{"id":"2518206234","title":"Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206234","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206234?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:02","pubTimestamp":1741629721,"startTime":"0","endTime":"0","summary":"On Monday, Arrowhead Pharmaceuticals, Inc. released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference  therapeutic designed to reduce liver production of complement component 3  as a potential therapy for various complement-mediated diseases.ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.Also Read: Veren Soars On Whitecap Merger Deal: Details. The company plans to present additional results at a medical meeting in 2025.Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.Maximum mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-stock-falls-early-180201122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","RNA","SSI","BK4585","ARWR","BK4505"],"gpt_icon":0},{"id":"2518277683","title":"Arrowhead data supports blockbuster potential of ARO-C3, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277683","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277683?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:20","pubTimestamp":1741623618,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line dat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-data-supports-blockbuster-potential-of-aro-c3-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-data-supports-blockbuster-potential-of-aro-c3-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARWR","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2518277662","title":"Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277662?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:15","pubTimestamp":1741623318,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Tr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-arrowhead-pharmaceuticals-driven-by-promising-aro-c3-trial-results-and-strategic-pipeline-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-arrowhead-pharmaceuticals-driven-by-promising-aro-c3-trial-results-and-strategic-pipeline-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARWR"],"gpt_icon":0},{"id":"2518216712","title":"Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518216712","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518216712?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:12","pubTimestamp":1741612364,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases.The second part of the phase 1/2 clinical study also showed reductions of 85% in AH50 and 100% in Wieslab AP, which are both markers of alternative pathway complement activity, in patients with IgA nephropathy, the company said.Arrowhead also reported that the therapy was generally well tolerated by the patients, with no serious or severe treatment adverse events.The study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of adult healthy volunteers and adult patients with complement-mediated renal disease.The company said it plans to present additional results at an upcoming medical meeting later this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","ARWR","BK4139"],"gpt_icon":0},{"id":"2518240622","title":"BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240622","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240622?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:43","pubTimestamp":1741606996,"startTime":"0","endTime":"0","summary":"BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA NephropathyMarch 10 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:ARROWHEAD P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","ARWR"],"gpt_icon":0},{"id":"2518924031","title":"Arrowhead announces topline results from ARO-C3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2518924031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518924031?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:35","pubTimestamp":1741606520,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-topline-results-from-aro-c3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-topline-results-from-aro-c3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA","BK4588","BK4585","ARWR","BK4505","BK4139"],"gpt_icon":0},{"id":"2518924715","title":"Arrowhead Pharmaceuticals Inc - Aro-C3 Generally Well-Tolerated in Patients With Igan","url":"https://stock-news.laohu8.com/highlight/detail?id=2518924715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518924715?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARWR","BK4588","BK4585"],"gpt_icon":0},{"id":"2518247169","title":"Arrowhead Pharmaceuticals Announces Topline Results From Part 2 of Phase 1/2 Study of Aro-C3 in Patients With Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247169?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARWR","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2518247147","title":"Arrowhead Pharmaceuticals Inc - No Serious or Severe Treatment Emergent Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247147","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247147?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARWR","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2518922845","title":"Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518922845","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518922845?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606200,"startTime":"0","endTime":"0","summary":"- ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria. - Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24. - Mean reduction in spot urine protein-to-creatinine ratio  of 41% by week 24. PASADENA, Calif., March 10, 2025----Arrowhead Pharmaceuticals, Inc.  today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference  therapeutic designed to reduce liver production of complement component 3  as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025.Patients with IgA nephropathy   received subcutaneous doses of ARO-C3  on Days 1, 29, and 113 and were followed through Day 169. Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-announces-topline-results-113000429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","ARWR","BK4588"],"gpt_icon":0},{"id":"2517031165","title":"Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517031165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517031165?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:48","pubTimestamp":1741272537,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said Thursday it has presented preclinical data supporting two RNA-interference-based investigational therapeutics it is developing, with the potential to reduce body weight and fat mass and preserve lean muscle mass compared with currently approved obesity therapies.Data from its ARO-INHBE candidate preclinical results showed a 19% suppression in body weight gain relative to vehicle controls, while data from its ARO-ALK7 candidate preclinical results showed a 39% suppression, the company said.Arrowhead is currently conducting phase 1/2 clinical studies of the two candidates. The company expects initial data from its ARO-INHBE study year-end 2025, and anticipates dosing in the ARO-ALK7 study to begin in the second quarter with initial data from the single-ascending dose portion of the study possible also by year-end 2025.The company presented the data at the RNA Leaders Europe Congress 2025 held March 4-6 in Basel, Switzerland.Price: 16.89, Change: -0.46, Per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK4139","BK4588","ARWR","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":134,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARWR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-10","symbol":"ARWR","fiscalQuarterEnding":"2024/12","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739163600000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2024-11-26","symbol":"ARWR","fiscalQuarterEnding":"2024/09","expectedEps":-0.63,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-1.38},{"market":"US","date":"2024-08-08","symbol":"ARWR","fiscalQuarterEnding":"2024/06","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-1.38},{"market":"US","date":"2024-05-09","symbol":"ARWR","fiscalQuarterEnding":"2024/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2024-02-06","symbol":"ARWR","fiscalQuarterEnding":"2023/12","expectedEps":-0.78,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1707195600000,"reportTimeType":"post","actualEps":-1.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARWR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARWR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1333,"buy":0.5333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1717819200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARWR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARWR","date":"2025-04-21","current":-2.215588,"percent":0.936118,"low":-296.588514,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"high":547.43255,"avg":-17.905558,"sd":115.567012,"marketCap":1417342767},"quantilePoints":[{"date":"2020-04-24","current":74.220832,"twenty":-18.275409,"median":-4.206053,"eighty":-1.052527,"marketCap":3953342610},{"date":"2020-05-01","current":62.140146,"twenty":-18.275409,"median":-4.153652,"eighty":-1.026185,"marketCap":3309869771},{"date":"2020-05-08","current":364.527936,"twenty":-18.275409,"median":-4.13929,"eighty":41.608706,"marketCap":3474539574},{"date":"2020-05-15","current":382.786365,"twenty":-18.275409,"median":-4.132262,"eighty":49.925866,"marketCap":3648571872},{"date":"2020-05-22","current":381.077974,"twenty":-18.275409,"median":-4.111179,"eighty":53.834436,"marketCap":3632288149},{"date":"2020-05-29","current":344.240792,"twenty":-18.275409,"median":-4.077636,"eighty":55.242895,"marketCap":3281170353},{"date":"2020-06-05","current":363.780515,"twenty":-18.275409,"median":-4.040903,"eighty":57.04414,"marketCap":3467415445},{"date":"2020-06-12","current":349.47274,"twenty":-18.275409,"median":-4.02418,"eighty":58.828247,"marketCap":3331039258},{"date":"2020-06-19","current":392.182515,"twenty":-18.275409,"median":-3.992874,"eighty":60.10843,"marketCap":3738132354},{"date":"2020-06-26","current":462.012999,"twenty":-18.275409,"median":-3.957597,"eighty":60.495173,"marketCap":4403729565},{"date":"2020-07-02","current":471.943021,"twenty":-18.275409,"median":-3.92846,"eighty":61.039647,"marketCap":4498378710},{"date":"2020-07-10","current":475.253029,"twenty":-18.275409,"median":-3.891958,"eighty":61.895529,"marketCap":4529928425},{"date":"2020-07-17","current":523.408301,"twenty":-18.275409,"median":-3.871005,"eighty":62.625798,"marketCap":4988925891},{"date":"2020-07-24","current":493.404684,"twenty":-18.275409,"median":-3.843641,"eighty":64.1913,"marketCap":4702942991},{"date":"2020-07-31","current":459.87751,"twenty":-18.275409,"median":-3.801907,"eighty":65.132645,"marketCap":4383374911},{"date":"2020-08-07","current":-168.551432,"twenty":-18.529695,"median":-3.789176,"eighty":65.318147,"marketCap":4115199234},{"date":"2020-08-14","current":-176.00909,"twenty":-18.968112,"median":-3.789176,"eighty":65.318147,"marketCap":4297278644},{"date":"2020-08-21","current":-178.020143,"twenty":-19.299259,"median":-3.789176,"eighty":65.318147,"marketCap":4346378709},{"date":"2020-08-28","current":-175.841502,"twenty":-19.749926,"median":-3.789176,"eighty":65.318147,"marketCap":4293186971},{"date":"2020-09-04","current":-150.99661,"twenty":-20.156605,"median":-3.789176,"eighty":65.318147,"marketCap":3686596580},{"date":"2020-09-11","current":-139.139773,"twenty":-20.285462,"median":-3.789176,"eighty":65.318147,"marketCap":3397110777},{"date":"2020-09-18","current":-180.575857,"twenty":-20.45098,"median":-3.789176,"eighty":65.318147,"marketCap":4408776709},{"date":"2020-09-25","current":-188.180154,"twenty":-20.855341,"median":-3.789176,"eighty":65.318147,"marketCap":4594436331},{"date":"2020-10-02","current":-183.592438,"twenty":-21.000912,"median":-3.789176,"eighty":65.318147,"marketCap":4482426807},{"date":"2020-10-09","current":-192.935458,"twenty":-21.181622,"median":-3.789176,"eighty":65.318147,"marketCap":4710537528},{"date":"2020-10-16","current":-206.887142,"twenty":-21.519563,"median":-3.789176,"eighty":65.318147,"marketCap":5051169232},{"date":"2020-10-23","current":-246.689245,"twenty":-21.724568,"median":-3.789176,"eighty":65.318147,"marketCap":6022941360},{"date":"2020-10-30","current":-240.069527,"twenty":-21.896478,"median":-3.789176,"eighty":65.318147,"marketCap":5861320311},{"date":"2020-11-06","current":-278.405237,"twenty":-22.1947,"median":-3.789176,"eighty":65.318147,"marketCap":6797290309},{"date":"2020-11-13","current":-287.1617,"twenty":-22.423055,"median":-3.789176,"eighty":65.318147,"marketCap":7011080177},{"date":"2020-11-20","current":-288.25102,"twenty":-22.812061,"median":-3.789176,"eighty":65.318147,"marketCap":7037676046},{"date":"2020-11-27","current":-76.551382,"twenty":-23.016886,"median":-3.789176,"eighty":65.318147,"marketCap":6472649005},{"date":"2020-12-04","current":-79.346559,"twenty":-23.27504,"median":-3.789176,"eighty":65.318147,"marketCap":6708989578},{"date":"2020-12-11","current":-90.004689,"twenty":-23.443255,"median":-3.789176,"eighty":65.318147,"marketCap":7610166460},{"date":"2020-12-18","current":-97.417984,"twenty":-23.662829,"median":-3.789176,"eighty":65.318147,"marketCap":8236982763},{"date":"2020-12-24","current":-102.315619,"twenty":-23.828206,"median":-3.789176,"eighty":65.318147,"marketCap":8651092550},{"date":"2020-12-31","current":-93.249524,"twenty":-23.877135,"median":-3.789176,"eighty":65.318147,"marketCap":7884527038},{"date":"2021-01-08","current":-97.077701,"twenty":-23.97186,"median":-3.789176,"eighty":65.318147,"marketCap":8208210867},{"date":"2021-01-15","current":-98.122854,"twenty":-24.454235,"median":-3.789176,"eighty":65.318147,"marketCap":8296581690},{"date":"2021-01-22","current":-99.739195,"twenty":-24.744147,"median":-3.789176,"eighty":65.318147,"marketCap":8433248195},{"date":"2021-01-29","current":-94.726725,"twenty":-24.828261,"median":-3.789176,"eighty":65.318147,"marketCap":8009428769},{"date":"2021-02-05","current":-91.510733,"twenty":-25.440997,"median":-3.789176,"eighty":65.318147,"marketCap":9390099332},{"date":"2021-02-12","current":-89.21462,"twenty":-26.042831,"median":-3.805477,"eighty":65.318147,"marketCap":9154490562},{"date":"2021-02-19","current":-90.53969,"twenty":-26.322299,"median":-3.843641,"eighty":65.318147,"marketCap":9290458619},{"date":"2021-02-26","current":-80.576379,"twenty":-26.916244,"median":-3.873833,"eighty":65.318147,"marketCap":8268103380},{"date":"2021-03-05","current":-69.79375,"twenty":-28.366158,"median":-3.907377,"eighty":65.320437,"marketCap":7161676290},{"date":"2021-03-12","current":-73.576774,"twenty":-29.531319,"median":-3.935488,"eighty":65.320437,"marketCap":7549859903},{"date":"2021-03-19","current":-68.175344,"twenty":-30.12048,"median":-3.970626,"eighty":65.320437,"marketCap":6995608434},{"date":"2021-03-26","current":-63.674153,"twenty":-30.547075,"median":-3.999327,"eighty":65.318147,"marketCap":6533732209},{"date":"2021-04-01","current":-67.841548,"twenty":-30.954671,"median":-4.016306,"eighty":65.318147,"marketCap":6961356938},{"date":"2021-04-09","current":-62.86495,"twenty":-31.342858,"median":-4.012792,"eighty":65.320437,"marketCap":6450698281},{"date":"2021-04-16","current":-68.42822,"twenty":-31.889554,"median":-4.012792,"eighty":65.320437,"marketCap":7021556536},{"date":"2021-04-23","current":-72.413545,"twenty":-32.415644,"median":-4.012792,"eighty":65.320437,"marketCap":7430498631},{"date":"2021-04-30","current":-73.597004,"twenty":-32.808234,"median":-4.012792,"eighty":65.320437,"marketCap":7551935751},{"date":"2021-05-07","current":-63.043178,"twenty":-45.932572,"median":-4.012792,"eighty":65.320437,"marketCap":6909154068},{"date":"2021-05-14","current":-69.168946,"twenty":-56.438632,"median":-4.033875,"eighty":65.320437,"marketCap":7580501519},{"date":"2021-05-21","current":-70.498571,"twenty":-57.863948,"median":-4.083069,"eighty":65.320437,"marketCap":7726220345},{"date":"2021-05-28","current":-68.950508,"twenty":-58.296058,"median":-4.111179,"eighty":65.320437,"marketCap":7556561997},{"date":"2021-06-04","current":-72.312558,"twenty":-58.476641,"median":-4.111179,"eighty":65.320437,"marketCap":7925022458},{"date":"2021-06-11","current":-84.250683,"twenty":-59.153827,"median":-4.111179,"eighty":65.320437,"marketCap":9233369349},{"date":"2021-06-18","current":-81.335007,"twenty":-59.54079,"median":-4.132262,"eighty":65.320437,"marketCap":8913828780},{"date":"2021-06-25","current":-85.779751,"twenty":-60.082539,"median":-4.188484,"eighty":65.320437,"marketCap":9400946000},{"date":"2021-07-02","current":-59.956551,"twenty":-60.959657,"median":-4.346124,"eighty":65.320437,"marketCap":6570878221},{"date":"2021-07-09","current":-63.764974,"twenty":-61.333721,"median":-4.547082,"eighty":65.320437,"marketCap":6988258574},{"date":"2021-07-16","current":-60.24147,"twenty":-61.430462,"median":-4.684632,"eighty":65.320437,"marketCap":6602103684},{"date":"2021-07-23","current":-64.933144,"twenty":-61.694887,"median":-4.836997,"eighty":65.320437,"marketCap":7116282972},{"date":"2021-07-30","current":-65.806897,"twenty":-62.139895,"median":-5.073506,"eighty":65.320437,"marketCap":7212041058},{"date":"2021-08-06","current":-53.65037,"twenty":-62.324426,"median":-5.25661,"eighty":65.320437,"marketCap":6754957196},{"date":"2021-08-13","current":-50.11453,"twenty":-62.324426,"median":-5.302386,"eighty":65.320437,"marketCap":6309770173},{"date":"2021-08-20","current":-49.625972,"twenty":-62.324426,"median":-5.37105,"eighty":65.320437,"marketCap":6248257212},{"date":"2021-08-27","current":-54.710294,"twenty":-62.324426,"median":-5.386309,"eighty":65.320437,"marketCap":6888409043},{"date":"2021-09-03","current":-55.935832,"twenty":-62.324426,"median":-5.401568,"eighty":65.320437,"marketCap":7042712742},{"date":"2021-09-10","current":-52.987918,"twenty":-62.324426,"median":-5.401568,"eighty":65.320437,"marketCap":6671549791},{"date":"2021-09-17","current":-53.7663,"twenty":-62.324426,"median":-5.500749,"eighty":65.320437,"marketCap":6769553492},{"date":"2021-09-24","current":-54.130649,"twenty":-62.324426,"median":-5.561784,"eighty":65.320437,"marketCap":6815427564},{"date":"2021-10-01","current":-51.836907,"twenty":-62.324426,"median":-9.576545,"eighty":65.320437,"marketCap":6526629425},{"date":"2021-10-08","current":-49.957198,"twenty":-62.324426,"median":-10.599494,"eighty":65.320437,"marketCap":6289960914},{"date":"2021-10-15","current":-54.78482,"twenty":-62.324426,"median":-12.617221,"eighty":65.320437,"marketCap":6897792376},{"date":"2021-10-22","current":-54.677172,"twenty":-62.324426,"median":-13.619752,"eighty":65.320437,"marketCap":6884238673},{"date":"2021-10-29","current":-52.847147,"twenty":-62.324426,"median":-14.182147,"eighty":65.320437,"marketCap":6653825717},{"date":"2021-11-05","current":-66.849736,"twenty":-62.691778,"median":-14.893608,"eighty":65.320437,"marketCap":8416849736},{"date":"2021-11-12","current":-61.227171,"twenty":-62.849328,"median":-15.49945,"eighty":65.320437,"marketCap":7708929388},{"date":"2021-11-19","current":-58.883745,"twenty":-62.849328,"median":-15.600362,"eighty":65.320437,"marketCap":7413875694},{"date":"2021-11-26","current":-53.447273,"twenty":-62.849328,"median":-15.768963,"eighty":65.320437,"marketCap":7527941490},{"date":"2021-12-03","current":-50.092904,"twenty":-62.849328,"median":-16.040498,"eighty":65.320437,"marketCap":7055485290},{"date":"2021-12-10","current":-52.000145,"twenty":-62.849328,"median":-16.358374,"eighty":65.320437,"marketCap":7324116359},{"date":"2021-12-17","current":-51.695877,"twenty":-62.849328,"median":-16.725153,"eighty":65.320437,"marketCap":7281260819},{"date":"2021-12-23","current":-52.133726,"twenty":-62.849328,"median":-16.774057,"eighty":65.320437,"marketCap":7342930987},{"date":"2021-12-31","current":-49.202363,"twenty":-62.849328,"median":-17.043029,"eighty":65.320437,"marketCap":6930054440},{"date":"2022-01-07","current":-43.747802,"twenty":-62.849328,"median":-17.532069,"eighty":65.318147,"marketCap":6161790486},{"date":"2022-01-14","current":-42.901789,"twenty":-62.849328,"median":-17.703232,"eighty":65.318147,"marketCap":6042631179},{"date":"2022-01-21","current":-37.729233,"twenty":-62.849328,"median":-17.9233,"eighty":65.318147,"marketCap":5314086994},{"date":"2022-01-28","current":-37.50079,"twenty":-62.849328,"median":-18.094464,"eighty":65.318147,"marketCap":5281911207},{"date":"2022-02-04","current":-28.67194,"twenty":-62.849328,"median":-18.47347,"eighty":65.318147,"marketCap":5246620871},{"date":"2022-02-11","current":-29.190628,"twenty":-62.849328,"median":-18.89431,"eighty":65.318147,"marketCap":5341534615},{"date":"2022-02-18","current":-25.502177,"twenty":-62.849328,"median":-19.299259,"eighty":65.318147,"marketCap":4666592433},{"date":"2022-02-25","current":-25.352334,"twenty":-62.849328,"median":-19.511471,"eighty":65.318147,"marketCap":4639172906},{"date":"2022-03-04","current":-24.735671,"twenty":-62.849328,"median":-19.873469,"eighty":65.318147,"marketCap":4526331010},{"date":"2022-03-11","current":-24.078666,"twenty":-62.849328,"median":-20.265536,"eighty":65.318147,"marketCap":4406106934},{"date":"2022-03-18","current":-27.30606,"twenty":-62.849328,"median":-20.427007,"eighty":65.318147,"marketCap":4996681344},{"date":"2022-03-25","current":-25.421493,"twenty":-62.849328,"median":-20.792261,"eighty":65.318147,"marketCap":4651828072},{"date":"2022-04-01","current":-28.354963,"twenty":-62.849328,"median":-20.994442,"eighty":65.318147,"marketCap":5188618027},{"date":"2022-04-08","current":-27.807459,"twenty":-62.849328,"median":-21.14622,"eighty":65.318147,"marketCap":5088431297},{"date":"2022-04-14","current":-27.012137,"twenty":-62.849328,"median":-21.291767,"eighty":65.318147,"marketCap":4942896888},{"date":"2022-04-22","current":-24.585828,"twenty":-62.849328,"median":-21.677169,"eighty":65.318147,"marketCap":4498911484},{"date":"2022-04-29","current":-23.692531,"twenty":-62.849328,"median":-21.85137,"eighty":65.318147,"marketCap":4335448924},{"date":"2022-05-06","current":-21.277749,"twenty":-62.849328,"median":-22.070043,"eighty":65.318147,"marketCap":3893572714},{"date":"2022-05-13","current":-29.922841,"twenty":-62.849328,"median":-22.230837,"eighty":65.318147,"marketCap":3345493368},{"date":"2022-05-20","current":-34.24482,"twenty":-62.849328,"median":-22.60735,"eighty":65.318147,"marketCap":3828707802},{"date":"2022-05-27","current":-32.343906,"twenty":-62.849328,"median":-22.835097,"eighty":65.318147,"marketCap":3616178040},{"date":"2022-06-03","current":-32.968086,"twenty":-62.849328,"median":-23.022811,"eighty":65.318147,"marketCap":3685963932},{"date":"2022-06-10","current":-28.863626,"twenty":-62.849328,"median":-23.265009,"eighty":65.318147,"marketCap":3227068824},{"date":"2022-06-17","current":-27.539606,"twenty":-62.849328,"median":-23.436785,"eighty":65.318147,"marketCap":3079038144},{"date":"2022-06-24","current":-32.589795,"twenty":-62.849328,"median":-23.562992,"eighty":65.320437,"marketCap":3643669452},{"date":"2022-07-01","current":-34.008387,"twenty":-62.849328,"median":-23.735995,"eighty":65.320437,"marketCap":3802273752},{"date":"2022-07-08","current":-39.465239,"twenty":-62.849328,"median":-23.824971,"eighty":65.320437,"marketCap":4412371626},{"date":"2022-07-15","current":-40.477169,"twenty":-62.849328,"median":-23.891697,"eighty":65.320437,"marketCap":4525509360},{"date":"2022-07-22","current":-40.354224,"twenty":-62.849328,"median":-23.943598,"eighty":65.320437,"marketCap":4511763654},{"date":"2022-07-29","current":-40.221822,"twenty":-62.849328,"median":-24.254281,"eighty":65.320437,"marketCap":4496960586},{"date":"2022-08-05","current":-31.604916,"twenty":-62.849328,"median":-24.559153,"eighty":65.320437,"marketCap":4864818339},{"date":"2022-08-12","current":-32.519506,"twenty":-62.849328,"median":-24.631934,"eighty":65.320437,"marketCap":5005597460},{"date":"2022-08-19","current":-29.301251,"twenty":-62.849328,"median":-24.78754,"eighty":65.320437,"marketCap":4510224313},{"date":"2022-08-26","current":-27.547714,"twenty":-62.849328,"median":-24.830151,"eighty":65.320437,"marketCap":4240309457},{"date":"2022-09-02","current":-27.107611,"twenty":-62.849328,"median":-25.139096,"eighty":65.320437,"marketCap":4172566121},{"date":"2022-09-09","current":-26.523099,"twenty":-62.849328,"median":-25.306228,"eighty":65.320437,"marketCap":4082594502},{"date":"2022-09-16","current":-23.786207,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3661315630},{"date":"2022-09-23","current":-21.269366,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3273908425},{"date":"2022-09-30","current":-22.727208,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3498308227},{"date":"2022-10-07","current":-21.743852,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3346944210},{"date":"2022-10-14","current":-22.018917,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3389283795},{"date":"2022-10-21","current":-22.961013,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3534296874},{"date":"2022-10-28","current":-24.666413,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3796802302},{"date":"2022-11-04","current":-23.35298,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3594630783},{"date":"2022-11-11","current":-23.71744,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3650730733},{"date":"2022-11-18","current":-21.124957,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3251680143},{"date":"2022-11-25","current":-20.28601,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3122544408},{"date":"2022-12-02","current":-20.428904,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3596774147},{"date":"2022-12-09","current":-18.207193,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3205613033},{"date":"2022-12-16","current":-19.12839,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3367801787},{"date":"2022-12-23","current":-23.060036,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":4060019152},{"date":"2022-12-30","current":-24.420759,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":4299592084},{"date":"2023-01-06","current":-22.506114,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3962493888},{"date":"2023-01-13","current":-22.168943,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3903130684},{"date":"2023-01-20","current":-20.326549,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3578753174},{"date":"2023-01-27","current":-20.236235,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3562852316},{"date":"2023-02-03","current":-22.267052,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3920403974},{"date":"2023-02-10","current":-23.21593,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3587232598},{"date":"2023-02-17","current":-23.657537,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3655468001},{"date":"2023-02-24","current":-22.872457,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3534160618},{"date":"2023-03-03","current":-22.676187,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3503833773},{"date":"2023-03-10","current":-18.442364,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2849640388},{"date":"2023-03-17","current":-17.033427,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2631936960},{"date":"2023-03-24","current":-17.026417,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2630853859},{"date":"2023-03-31","current":-17.804487,"twenty":-62.849328,"median":-25.329281,"eighty":65.318147,"marketCap":2751078140},{"date":"2023-04-06","current":-17.713362,"twenty":-62.849328,"median":-25.329281,"eighty":65.318147,"marketCap":2736997819},{"date":"2023-04-14","current":-21.379404,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3303459971},{"date":"2023-04-21","current":-20.972845,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3240640076},{"date":"2023-04-28","current":-24.505704,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3786523298},{"date":"2023-05-05","current":-28.503078,"twenty":-62.849328,"median":-25.406021,"eighty":65.320437,"marketCap":4281361861},{"date":"2023-05-12","current":-28.524429,"twenty":-62.849328,"median":-25.564592,"eighty":65.322728,"marketCap":4284568873},{"date":"2023-05-19","current":-25.820017,"twenty":-62.849328,"median":-25.767729,"eighty":65.327309,"marketCap":3878347273},{"date":"2023-05-26","current":-23.891344,"twenty":-62.849498,"median":-25.820017,"eighty":65.341771,"marketCap":3588647132},{"date":"2023-06-02","current":-24.6742,"twenty":-62.849668,"median":-25.85766,"eighty":65.356234,"marketCap":3706237596},{"date":"2023-06-09","current":-25.407238,"twenty":-62.849668,"median":-25.915884,"eighty":65.356234,"marketCap":3816345029},{"date":"2023-06-16","current":-25.435706,"twenty":-62.849668,"median":-25.915884,"eighty":65.356234,"marketCap":3820621046},{"date":"2023-06-23","current":-25.300485,"twenty":-62.849839,"median":-25.72783,"eighty":65.370696,"marketCap":3800309966},{"date":"2023-06-30","current":-25.570926,"twenty":-62.850009,"median":-25.674346,"eighty":65.385159,"marketCap":3840932126},{"date":"2023-07-07","current":-24.581681,"twenty":-62.850179,"median":-25.548283,"eighty":65.399621,"marketCap":3692340541},{"date":"2023-07-14","current":-24.546097,"twenty":-62.853133,"median":-25.4286,"eighty":65.437987,"marketCap":3686995520},{"date":"2023-07-21","current":-24.780953,"twenty":-62.853133,"median":-25.333526,"eighty":65.437987,"marketCap":3722272659},{"date":"2023-07-28","current":-25.499758,"twenty":-62.853133,"median":-25.303356,"eighty":65.437987,"marketCap":3830242084},{"date":"2023-08-04","current":-23.001735,"twenty":-62.853133,"median":-25.189784,"eighty":65.437987,"marketCap":3455021606},{"date":"2023-08-11","current":-17.14665,"twenty":-62.853133,"median":-25.145063,"eighty":65.437987,"marketCap":3105378341},{"date":"2023-08-18","current":-17.176244,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":3110737987},{"date":"2023-08-25","current":-16.596205,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":3005688944},{"date":"2023-09-01","current":-16.359455,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":2962811783},{"date":"2023-09-08","current":-17.886495,"twenty":-62.853133,"median":-25.073568,"eighty":65.437987,"marketCap":3239369468},{"date":"2023-09-15","current":-18.075895,"twenty":-62.856087,"median":-25.01581,"eighty":65.476352,"marketCap":3273671196},{"date":"2023-09-22","current":-16.116786,"twenty":-62.856087,"median":-24.951758,"eighty":65.476352,"marketCap":2918862694},{"date":"2023-09-29","current":-15.939223,"twenty":-62.856087,"median":-24.830151,"eighty":65.476352,"marketCap":2886704823},{"date":"2023-10-06","current":-15.122434,"twenty":-62.859042,"median":-24.823525,"eighty":65.514718,"marketCap":2738778620},{"date":"2023-10-13","current":-15.317753,"twenty":-62.859042,"median":-24.823525,"eighty":65.514718,"marketCap":2774152277},{"date":"2023-10-20","current":-15.004059,"twenty":-62.861996,"median":-24.825913,"eighty":65.553083,"marketCap":2717340040},{"date":"2023-10-23","current":-15.057327,"twenty":-62.861996,"median":-24.825913,"eighty":65.553083,"marketCap":2726987401},{"date":"2023-11-03","current":-15.483478,"twenty":-62.913621,"median":-24.830151,"eighty":65.661983,"marketCap":2804166290},{"date":"2023-11-10","current":-15.826766,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2866338172},{"date":"2023-11-17","current":-15.424291,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2793447000},{"date":"2023-11-24","current":-17.235431,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":3121457277},{"date":"2023-12-01","current":-11.082764,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2275014400},{"date":"2023-12-08","current":-12.837959,"twenty":-62.897398,"median":-24.823525,"eighty":65.638472,"marketCap":2635312111},{"date":"2023-12-15","current":-14.941857,"twenty":-62.897398,"median":-24.799067,"eighty":65.638472,"marketCap":3067189595},{"date":"2023-12-22","current":-15.051762,"twenty":-62.897398,"median":-24.799067,"eighty":65.638472,"marketCap":3089750359},{"date":"2023-12-29","current":-16.224082,"twenty":-62.913621,"median":-24.810593,"eighty":65.661983,"marketCap":3330398510},{"date":"2024-01-05","current":-20.727623,"twenty":-62.929845,"median":-24.815865,"eighty":65.685495,"marketCap":4254862911},{"date":"2024-01-12","current":-22.510451,"twenty":-62.929845,"median":-24.780146,"eighty":65.685495,"marketCap":4620832875},{"date":"2024-01-19","current":-19.905242,"twenty":-62.946069,"median":-24.739411,"eighty":65.709006,"marketCap":4086048483},{"date":"2024-01-26","current":-20.061314,"twenty":-62.929845,"median":-24.737541,"eighty":65.685495,"marketCap":4118086258},{"date":"2024-02-02","current":-19.419562,"twenty":-62.929845,"median":-24.715611,"eighty":65.685495,"marketCap":3986350531},{"date":"2024-02-09","current":-12.877492,"twenty":-62.929845,"median":-24.670306,"eighty":65.685495,"marketCap":3822219796},{"date":"2024-02-16","current":-12.343191,"twenty":-62.929845,"median":-24.583754,"eighty":65.685495,"marketCap":3663631746},{"date":"2024-02-23","current":-12.606167,"twenty":-62.929845,"median":-24.5259,"eighty":65.685495,"marketCap":3741686802},{"date":"2024-03-01","current":-13.39927,"twenty":-62.849839,"median":-24.403759,"eighty":65.661983,"marketCap":3977090939},{"date":"2024-03-08","current":-13.858435,"twenty":-62.78865,"median":-24.183136,"eighty":65.661983,"marketCap":4113377544},{"date":"2024-03-15","current":-11.445732,"twenty":-62.78865,"median":-24.078666,"eighty":65.661983,"marketCap":3397253381},{"date":"2024-03-22","current":-11.783844,"twenty":-62.78865,"median":-23.934586,"eighty":65.661983,"marketCap":3497609882},{"date":"2024-03-28","current":-11.980033,"twenty":-62.78865,"median":-23.867826,"eighty":65.661983,"marketCap":3555841431},{"date":"2024-04-05","current":-10.898908,"twenty":-62.771965,"median":-23.697907,"eighty":65.685495,"marketCap":3234948424},{"date":"2024-04-12","current":-10.719416,"twenty":-62.450545,"median":-23.597561,"eighty":65.685495,"marketCap":3181672751},{"date":"2024-04-19","current":-9.437928,"twenty":-62.450545,"median":-23.514443,"eighty":65.685495,"marketCap":2801309225},{"date":"2024-04-26","current":-9.129035,"twenty":-62.427752,"median":-23.37361,"eighty":65.661983,"marketCap":2709625509},{"date":"2024-05-03","current":-10.072411,"twenty":-62.427752,"median":-23.21593,"eighty":65.661983,"marketCap":2989632534},{"date":"2024-05-10","current":-6.482305,"twenty":-62.427752,"median":-23.186475,"eighty":65.370696,"marketCap":3068567760},{"date":"2024-05-17","current":-6.595323,"twenty":-62.427752,"median":-23.186475,"eighty":64.679241,"marketCap":3105005750},{"date":"2024-05-24","current":-6.508265,"twenty":-62.427752,"median":-23.186475,"eighty":63.492771,"marketCap":3064019674},{"date":"2024-05-31","current":-6.009659,"twenty":-62.427752,"median":-23.186475,"eighty":62.516156,"marketCap":2829281239},{"date":"2024-06-07","current":-6.513541,"twenty":-62.427752,"median":-23.186475,"eighty":61.77678,"marketCap":3066503678},{"date":"2024-06-14","current":-6.991043,"twenty":-62.450545,"median":-23.188804,"eighty":61.001953,"marketCap":3291306095},{"date":"2024-06-21","current":-6.27611,"twenty":-62.473339,"median":-23.191133,"eighty":60.436538,"marketCap":2954723471},{"date":"2024-06-28","current":-6.777354,"twenty":-62.570212,"median":-23.208812,"eighty":59.933947,"marketCap":3190703908},{"date":"2024-07-05","current":-6.61379,"twenty":-62.570212,"median":-23.208812,"eighty":58.878506,"marketCap":3113699766},{"date":"2024-07-12","current":-7.452716,"twenty":-62.570212,"median":-23.208812,"eighty":57.044321,"marketCap":3508656497},{"date":"2024-07-15","current":-7.415782,"twenty":-62.570212,"median":-23.208812,"eighty":56.809508,"marketCap":3491268465},{"date":"2024-08-02","current":-7.244303,"twenty":-62.781052,"median":-23.464332,"eighty":50.761782,"marketCap":3410538315},{"date":"2024-08-09","current":-5.966088,"twenty":-62.781052,"median":-23.464332,"eighty":47.94868,"marketCap":3213549832},{"date":"2024-08-16","current":-5.229847,"twenty":-62.781052,"median":-23.464332,"eighty":-5.237233,"marketCap":2816984108},{"date":"2024-08-23","current":-5.624509,"twenty":-62.781052,"median":-23.464332,"eighty":-5.400175,"marketCap":3029563227},{"date":"2024-08-30","current":-5.557578,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2993511797},{"date":"2024-09-06","current":-5.366017,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2890330120},{"date":"2024-09-13","current":-4.670166,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2515519569},{"date":"2024-09-20","current":-4.879037,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2628024892},{"date":"2024-09-27","current":-4.528226,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2439065675},{"date":"2024-10-04","current":-4.350513,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2343342914},{"date":"2024-10-11","current":-4.085097,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2200380349},{"date":"2024-10-18","current":-4.809798,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2590730310},{"date":"2024-10-25","current":-4.599773,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2477603410},{"date":"2024-10-31","current":-4.548998,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2450254050},{"date":"2024-11-08","current":-4.936736,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2659103710},{"date":"2024-11-15","current":-4.941352,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2661590016},{"date":"2024-11-22","current":-4.218959,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2272483208},{"date":"2024-11-29","current":-5.402946,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":3239028525},{"date":"2024-12-06","current":-4.628725,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2774888056},{"date":"2024-12-13","current":-4.595514,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2754978545},{"date":"2024-12-20","current":-4.04754,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2426471619},{"date":"2024-12-27","current":-4.053767,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2430204652},{"date":"2025-01-03","current":-4.078674,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2445136785},{"date":"2025-01-10","current":-4.099431,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2457580229},{"date":"2025-01-17","current":-3.947908,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2366743086},{"date":"2025-01-24","current":-4.468899,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2679073536},{"date":"2025-01-31","current":-4.199063,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2517308761},{"date":"2025-02-07","current":-4.27277,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2561495982},{"date":"2025-02-14","current":-3.766894,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2409734901},{"date":"2025-02-21","current":-4.131559,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2643016406},{"date":"2025-02-28","current":-3.733384,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2388298222},{"date":"2025-03-07","current":-3.483047,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":2228153621},{"date":"2025-03-14","current":-2.970544,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1900298532},{"date":"2025-03-21","current":-2.978429,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1905342457},{"date":"2025-03-28","current":-2.720206,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1740153931},{"date":"2025-04-04","current":-2.377224,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1520743218},{"date":"2025-04-11","current":-2.189963,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":1400950013},{"date":"2025-04-17","current":-2.237271,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":1431213559},{"date":"2025-04-21","current":-2.215588,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1417342767}],"updateTime":1745314821422}}}